Historically, blood has been a source of protein biomarkers such as prostate-specific antigen (PSA).8 More recently, with the advent of DNA-analyses technologies for cancer genomes, DNA released into the blood from tumor cells (i.e., circulating tumor DNA, ctDNA) has become a mainstream target for developing liquid biopsy-based clinical tests. Here, KLK3 is linked to cancer.